title: Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression.
authors.affiliation: Department of Surgery, Mount Sinai Medical Center New York, NY 10029.
authors.forename: E
authors.initials: E
authors.lastname: Mor
authors.forename: P A
authors.initials: PA
authors.lastname: Sheiner
authors.forename: M E
authors.initials: ME
authors.lastname: Schwartz
authors.forename: S
authors.initials: S
authors.lastname: Emre
authors.forename: S
authors.initials: S
authors.lastname: Guy
authors.forename: C M
authors.initials: CM
authors.lastname: Miller
mesh_terms: D016572:Cyclosporine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D016031:Liver Transplantation / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D016572:Cyclosporine; D016559:Tacrolimus